Mediar Therapeutics

2 additional undisclosed programs RD/Clin0 fibrosis

Mediar Therapeutics is a pre-clinical stage biotech company in Cambridge, MA, developing treatments that target fibrotic mediators that drive disease progression. This novel approach addresses the underlying mechanisms behind fibrosis, a condition that causes the scarring of organs and tissues. This is different from traditional approaches that focus on initiators of fibrosis that may cause adverse effects to inflammatory pathways. They aim to address late-stage fibrosis, a condition with little to no current treatment options. Their team’s expertise in antibody engineering is helping accelerate treatments for halting or reversing fibrosis to the clinic. Mediar was founded in 2019 by current CSO, Paul Yaworsky, who previously spent over 20 years in drug discovery and development at Pfizer.